Sputnik V was initially registered for use in Russia in August 2020, making it the first registered Covid-19 vaccine out of 165 being developed across the world. Bloomberg
A Russian medic holds a dose of Sputnik V vaccine. The UAE clinical trials into the Russian Sputnik V vaccine have moved into the final monitoring phase. EPA
The next step in the UAE trial involves monitoring volunteers’ immune response over 180 days. Bloomberg
In the UAE 1,000 trial volunteers have received their second dose.The vaccine is produced at Russia's biotech company Biocad in Strelna outside Saint Petersburg. AFP
Recent interim results from Phase III of clinical trials into the Sputnik V have shown a high efficacy of 91.6%. AFP
Sputnik V is developed by the Gamaleya Research Institute of Epidemiology and Microbiology in co-ordination with the Russian Defence Ministry. It is tested at Russia's biotechnology company Biocad in Strelna, outside Saint Petersburg. EPA
Kirill Dmitriev expects vaccines to be mixed in an attempt to boost dose numbers and tackle new strains. Sputnik / AFP
A vial of the Sputnik V Covid-19 vaccine. Data published in The Lancet showed the vaccine is safe, and provides strong immunogenicity. Bloomberg
A health worker removes a box containing vials of the Sputnik V Covid-19 vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology, and the Russian Direct Investment Fund. Bloomberg
Sputnik V was initially registered for use in Russia in August 2020, making it the first registered Covid-19 vaccine out of 165 being developed across the world. Bloomberg
A Russian medic holds a dose of Sputnik V vaccine. The UAE clinical trials into the Russian Sputnik V vaccine have moved into the final monitoring phase. EPA
The next step in the UAE trial involves monitoring volunteers’ immune response over 180 days. Bloomberg
In the UAE 1,000 trial volunteers have received their second dose.The vaccine is produced at Russia's biotech company Biocad in Strelna outside Saint Petersburg. AFP
Recent interim results from Phase III of clinical trials into the Sputnik V have shown a high efficacy of 91.6%. AFP
Sputnik V is developed by the Gamaleya Research Institute of Epidemiology and Microbiology in co-ordination with the Russian Defence Ministry. It is tested at Russia's biotechnology company Biocad in Strelna, outside Saint Petersburg. EPA
Kirill Dmitriev expects vaccines to be mixed in an attempt to boost dose numbers and tackle new strains. Sputnik / AFP
A vial of the Sputnik V Covid-19 vaccine. Data published in The Lancet showed the vaccine is safe, and provides strong immunogenicity. Bloomberg
A health worker removes a box containing vials of the Sputnik V Covid-19 vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology, and the Russian Direct Investment Fund. Bloomberg
Sputnik V was initially registered for use in Russia in August 2020, making it the first registered Covid-19 vaccine out of 165 being developed across the world. Bloomberg